Myrcludex B

Drug Profile

Myrcludex B

Alternative Names: Myrcludex-B

Latest Information Update: 27 Feb 2017

Price : $50

At a glance

  • Originator INSERM; University of Heidelberg; Vision7
  • Developer Hepatera; MYR GmbH; Vision7
  • Class Antivirals; Lipopeptides
  • Mechanism of Action Cell surface receptor antagonists; Sodium-bile acid cotransporter-inhibitors; Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis B; Hepatitis D

Most Recent Events

  • 11 Nov 2016 Efficacy and adverse events data from a phase IIa trial in Hepatitis D presented at the The Liver Meeting® 2016: 67th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD - 2016)
  • 25 May 2016 Hepatera and MYR GmbH initiate a phase II MYR 203 trial for Hepatitis B and hepatitis D (Combination therapy) in Russia
  • 22 Mar 2016 Phase-II clinical trials in Hepatitis B (Combination therapy) in Germany (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top